Article Menu

Export Article

More by Authors Links

Article Data

  • Views 1516
  • Dowloads 134

Original Research

Open Access

Anti-Hsp20 antibody concentrations inversely correlated with tumor progression in ovarian cancer

  • Yanhui Zhu1,*,
  • Qingchao Tian2
  • Naian Qiao3
  • Yin Cheng4
  • Haiying Li5

1Medical Informatics Center, Peking University, Beijing, China

2Department of Obstetrics and Gynecology, Jinan third People’s Hospital, Jinan, China

3Department of Radiotherapy, Shandong University Qilu Hospital, Jinan, China

4Department of Science and Education, Jinan third People’s Hospital, Jinan, China

5Division of Ultrasonography, Shandong University Qilu Hospital, Jinan, China

DOI: 10.12892/ejgo2623.2015 Vol.36,Issue 4,August 2015 pp.394-396

Published: 10 August 2015

*Corresponding Author(s): Yanhui Zhu E-mail: gzyh@hsc.pku.edu.cn

PDF (131.76 kB) View Full-text

Abstract

Purpose: To investigate the serum concentrations of anti-heat shock protein 20 (anti-Hsp20) antibodies in women with ovarian cancer at different clinical stages, and the relationship between these concentrations and tumor progression. Materials and Methods: Blood samples were obtained from 72 patients undergoing surgery for ovarian cancer, 21 women with ovarian carcinoid, and 42 healthy women. Anti-Hsp20 antibody concentrations were determined by enzyme-linked immunosorbent assay. Results: Mean anti- Hsp20 antibody concentrations were significantly lower in patients with ovarian cancer than in the control group. The anti-Hsp20 antibody concentrations were negatively correlated with ovarian cancer malignancy. Conclusions: The present findings suggest that anti-Hsp20 antibodies may play a protective role against ovarian cancer progression, and that anti-Hsp20 antibodies may be a new index for the early diagnosis and treatment of ovarian cancer.

Keywords

Heat shock protein; Hsp20; Ovarian cancer.

Cite and Share

Yanhui Zhu,Qingchao Tian,Naian Qiao,Yin Cheng,Haiying Li. Anti-Hsp20 antibody concentrations inversely correlated with tumor progression in ovarian cancer. European Journal of Gynaecological Oncology. 2015. 36(4);394-396.

URL:

https://www.ejgo.net/articles/10.12892/ejgo2623.2015

References

[1] Kurashina R., Ohyashiki J.H., Kobayashi C., Hamamura R., Zhang Y., Hirano T., et al.: “Anti-proliferative activity of heat shock protein (Hsp) 90 inhibitors via beta-catenin/TCF7L2 pathway in adult T cell leukemia cells”. Cancer Lett., 2009, 284, 62.

[2] Loriot Y, Calderaro J, Soria JC, Deutsch E, Vielh P.: “Anti-apoptotic mechanisms in small-cell lung carcinoma”. Ann. Pathol. 2010, 30, 17. [Article in French].

[3] Parcellier A., Schmitt E., Brunet M., Hammann A., Solary E., Garrido C.: “Small heat shock proteins Hsp27 and alphaB-crystallin: cytoprotective and oncogenic functions”. Antioxid. Redox. Signal., 2005, 7, 404.

[4] Concannon C.G., Gorman A.M., Samali A.: “On the role of Hsp27 in regulating apoptosis”. Apoptosis, 2003, 8, 61.

[5] Garrido C., Schmitt E., Candé C., Vahsen N., Parcellier A., Kroemer G.: “Hsp27 and Hsp70: potentially oncogenic apoptosis inhibitors”. Cell Cycle, 2003, 2, 579.

[6] Zhu Y.H., Ma T.M., Wang X.: “Gene transfer of heat-shock protein 20 protects against ischemia/reperfusion injury in rat hearts”. Acta Pharmacol. Sin., 2005, 26, 1193.

[7] Zhu Y.H., Wang X.: “Overexpression of heat-shock protein 20 in rat heart myogenic cells confers protection against simulated ischemia/ reperfusion injury”. Acta Pharmacol. Sin., 2005, 26, 1076.

[8] Olejek A., Damasiewicz-Bodzek A., Bodzek P., Wielkoszyński T., Zamłyński J., Stołtny P., et al.: “Concentrations of antibodies against heat shock protein 27 in the sera of women with ovarian carcinoma”. Int. J. Gynecol. Cancer, 2009, 19, 1516.

Submission Turnaround Time

Top